<p><strong>目前无需股东采取行动</strong></p>
<p>佛罗里达州德尔雷海滩，2025 年 12 月 11 日（全球新闻通讯社）—— PetMed Express, Inc.，以 PetMeds 和 PetCareRx 的母公司名义运营（纳斯达克：PETS）（“公司” 或 “PetMeds”），今天确认已收到来自新加坡投资公司 SilverCape Investments Limited 的非正式且不具约束力的收购提议，拟以每股 4 美元现金收购公司所有流通股份，受尽职调查和签署双方可接受的最终协议等多项条件的限制，但不受任何融资条件的限制。虽然 PetMeds 通常不会对私下提交的非正式收购提议公开评论，但 SilverCape 已在 2025 年 12 月 11 日向美国证券交易委员会提交的 Schedule 13D 修正案中公开披露了其提议及相关条款。</p>
<p>PetMeds 董事会将根据其信托责任，并在财务和法律顾问的协助下，仔细审查和考虑 SilverCape 的收购提议，以确定其认为符合 PetMeds 及其股东最佳利益的行动方案。PetMeds 指出，SilverCape 的信函并不构成可接受的正式报价，因此股东目前无需采取任何行动。</p>
<p><strong>关于 PetMed Express, Inc.</strong></p>
<p>PetMeds 成立于 1996 年，是直接面向消费者的宠物医疗保健领域的先驱。作为一家值得信赖的全国在线药房，PetMeds 在所有 50 个州均持有执照，并配备了专注于支持宠物健康的专业药剂师，服务于宠物及其主人，以及为他们提供服务的兽医。通过其 PETS 品牌系列和 PetCareRx 子公司，公司提供全面的宠物健康解决方案——包括知名品牌和仿制药、复合药物以及更适合宠物的非处方补充剂和营养品。PetMeds 和 PetCareRx 专注于价值、便利和关怀，帮助宠物主人让他们的狗、猫和马过上更长、更健康的生活。欲了解更多信息，请访问 www.PetMeds.com 和 www.PetCareRx.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。本新闻稿中所有与历史事实无关的声明应视为前瞻性声明。诸如 “可能”、“可以”、“期望”、“预测”、“展望”、“战略”、“打算”、“计划”、“寻求”、“预期”、“相信”、“估计”、“预测”、“潜在”、“努力”、“目标”、“继续”、“可能”、“将”、“会” 等类似词汇和表达旨在表示前瞻性声明。前瞻性声明基于公司对未来事件的当前预期和假设，这些事件面临风险和不确定性。由于多种因素，实际结果可能与预期结果有重大差异，包括但不限于公司董事会审计委员会现已完成的调查结果、公司截至 2025 年 6 月 30 日和 2025 年 9 月 30 日的季度报告在提交时可能比预期更长的风险，以及公司在证券交易委员会的文件中不时描述的其他风险，包括但不限于截至 2025 年 3 月 31 日的年度报告（Form 10-K）以及后续的 Form 10-Q 和定期的 Form 8-K 文件。您不应对这些前瞻性声明过于依赖，这些声明仅适用于本新闻稿的日期，并且不应被视为公司在任何后续日期的观点。公司没有义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
<p><strong>投资者联系</strong></p>
<p>ICR, LLC</p>
<p>Reed Anderson</p>
<p>(646) 277-1260</p>
<p>investor@petmeds.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EYzROU00zTXpFM056QTBJekl3TVRnNU5UTT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EYzROU00zTXpFM056QTBJekl3TVRnNU5UTT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png"/></p>

PETS

<p>PetMed Express 收到了 SilverCape Investments Limited 提出的非正式、非约束性的收购提议，拟以每股 4 美元现金收购所有流通股份。该提议需满足尽职调查和最终协议等条件。PetMed 的董事会将审查该提议，目前不需要股东采取任何行动。SilverCape 的提议并不是正式报价，PetMed 强调股东目前无需采取行动</p>

<p><strong>No Stockholder Action Required at this Time</strong></p>
<div class="lb-trans"><p><strong>目前无需股东采取行动</strong></p>
</div><p>DELRAY BEACH, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company” or “PetMeds”), today confirmed that it has received an unsolicited and non-binding acquisition proposal from SilverCape Investments Limited, a Singapore-based investment firm, to acquire all of the outstanding shares of the Company for $4 per share in cash, subject to various conditions such as due diligence and the execution of a mutually acceptable definitive agreement, but not subject to any financing contingency. While PetMeds would typically not publicly comment on privately submitted and non-binding acquisition proposals, SilverCape has publicly disclosed its proposal and the terms thereof in an amendment to its Schedule 13D that was filed with the U.S. Securities and Exchange Commission on December 11, 2025.</p>
<div class="lb-trans"><p>佛罗里达州德尔雷海滩，2025 年 12 月 11 日（全球新闻通讯社）—— PetMed Express, Inc.，以 PetMeds 和 PetCareRx 的母公司名义运营（纳斯达克：PETS）（“公司” 或 “PetMeds”），今天确认已收到来自新加坡投资公司 SilverCape Investments Limited 的非正式且不具约束力的收购提议，拟以每股 4 美元现金收购公司所有流通股份，受尽职调查和签署双方可接受的最终协议等多项条件的限制，但不受任何融资条件的限制。虽然 PetMeds 通常不会对私下提交的非正式收购提议公开评论，但 SilverCape 已在 2025 年 12 月 11 日向美国证券交易委员会提交的 Schedule 13D 修正案中公开披露了其提议及相关条款。</p>
</div><p>The PetMeds Board of Directors, consistent with its fiduciary duties and in consultation with its financial and legal advisors, will carefully review and consider SilverCape’s acquisition proposal to determine the course of action that it believes is in the best interests of PetMeds and its stockholders. PetMeds notes that SilverCape’s letter does not constitute a formal offer capable of acceptance and, as such, stockholders do not need to take any action at this time.</p>
<div class="lb-trans"><p>PetMeds 董事会将根据其信托责任，并在财务和法律顾问的协助下，仔细审查和考虑 SilverCape 的收购提议，以确定其认为符合 PetMeds 及其股东最佳利益的行动方案。PetMeds 指出，SilverCape 的信函并不构成可接受的正式报价，因此股东目前无需采取任何行动。</p>
</div><p><strong>About PetMed Express, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 PetMed Express, Inc.</strong></p>
</div><p>Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.</p>
<div class="lb-trans"><p>PetMeds 成立于 1996 年，是直接面向消费者的宠物医疗保健领域的先驱。作为一家值得信赖的全国在线药房，PetMeds 在所有 50 个州均持有执照，并配备了专注于支持宠物健康的专业药剂师，服务于宠物及其主人，以及为他们提供服务的兽医。通过其 PETS 品牌系列和 PetCareRx 子公司，公司提供全面的宠物健康解决方案——包括知名品牌和仿制药、复合药物以及更适合宠物的非处方补充剂和营养品。PetMeds 和 PetCareRx 专注于价值、便利和关怀，帮助宠物主人让他们的狗、猫和马过上更长、更健康的生活。欲了解更多信息，请访问 www.PetMeds.com 和 www.PetCareRx.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the results of the now completed investigation by the Audit Committee of the Company’s Board of Directors, the risk that the completion of the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 may take longer than expected, and other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。本新闻稿中所有与历史事实无关的声明应视为前瞻性声明。诸如 “可能”、“可以”、“期望”、“预测”、“展望”、“战略”、“打算”、“计划”、“寻求”、“预期”、“相信”、“估计”、“预测”、“潜在”、“努力”、“目标”、“继续”、“可能”、“将”、“会” 等类似词汇和表达旨在表示前瞻性声明。前瞻性声明基于公司对未来事件的当前预期和假设，这些事件面临风险和不确定性。由于多种因素，实际结果可能与预期结果有重大差异，包括但不限于公司董事会审计委员会现已完成的调查结果、公司截至 2025 年 6 月 30 日和 2025 年 9 月 30 日的季度报告在提交时可能比预期更长的风险，以及公司在证券交易委员会的文件中不时描述的其他风险，包括但不限于截至 2025 年 3 月 31 日的年度报告（Form 10-K）以及后续的 Form 10-Q 和定期的 Form 8-K 文件。您不应对这些前瞻性声明过于依赖，这些声明仅适用于本新闻稿的日期，并且不应被视为公司在任何后续日期的观点。公司没有义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>ICR, LLC</p>
<div class="lb-trans"><p>ICR, LLC</p>
</div><p>Reed Anderson</p>
<div class="lb-trans"><p>Reed Anderson</p>
</div><p>(646) 277-1260</p>
<div class="lb-trans"><p>(646) 277-1260</p>
</div><p>investor@petmeds.com</p>
<div class="lb-trans"><p>investor@petmeds.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EYzROU00zTXpFM056QTBJekl3TVRnNU5UTT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMDc4NSM3MzE3NzA0IzIwMTg5NTM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NTYxYTdjMWItODAxNi00M2JmLTg3ZmUtOTAyMGU0NGE4M2E3LTEwMzA1MjYtMjAyNS0xMi0xMS1lbg==/tiny/PetMed-Express-Inc-.png"/></p>

PetMed Express 对 SilverCape Investments Limited 提出的未经请求且不具约束力的收购提案发表了评论 | PETS 股票新闻